You have 9 free searches left this month | for more free features.

T cell leukoma/lymphoma

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail

Recruiting
  • T-cell Lymphoma
  • +30 more
  • Optional Blood Sample
  • Optional Nail Sample
  • Duarte, California
  • +25 more
Jul 28, 2023

Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral Trial (SGN-35T)

Not yet recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +5 more
  • (no location specified)
Nov 2, 2023

Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

Recruiting
  • Peripheral T Cell Lymphoma
  • +2 more
  • Chidamide combined with Duvillisib
  • Xiamen, Fujian, China
    The First Affiliated Hosptial of Xiamen University
Nov 28, 2023

ASCT Versus Chemotherapy as First-Line Consolidation Therapy

Completed
  • T-cell Lymphoma Adults
  • consolidation with ASCT
  • (no location specified)
Nov 25, 2023

T Cell Lymphoma Trial in New Haven (Mogamulizumab, DA-EPOCH Protocol)

Not yet recruiting
  • T Cell Lymphoma
  • New Haven, Connecticut
    Yale Smilow Cancer Hospital
Aug 14, 2023

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

Recruiting
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Apr 7, 2023

T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)

Not yet recruiting
  • T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
  • CD7-CART01
  • (no location specified)
Sep 26, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma Trial in New York (Tazemetostat Pill)

Not yet recruiting
  • Follicular Lymphoma
  • +3 more
  • Tazemetostat Pill
  • New York, New York
    Weill Cornell Medicine/NewYork-Presbyterian Hospital
Jun 28, 2023

Circulating Tumor DNA Sequencing in Peripheral T-cell Lymphomas

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • circulating tumoral DNA detection
  • Rouen, France
    Centre Henri Becquerel
Oct 13, 2023

Cutaneous T-cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Cutaneous T-cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 8, 2023

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Wuhan (Duvelisib, Chidamide)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • Duvelisib, Chidamide
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Jul 27, 2023

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
  • (no location specified)
Jun 28, 2023

nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma Trial in Beijing (XPO1 inhibitor)

Recruiting
  • nk/T-cell Lymphoma
  • +2 more
  • XPO1 inhibitor
  • Beijing, Haidian, China
    ChinaPLAGH
Apr 18, 2023

B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)

Recruiting
  • B-Cell Non Hodgkin Lymphoma
  • B-Cell Acute Lymphoblastic Leukemia
  • anti-CD19 CAR T-cells
  • Hanoi, Vietnam
    Vinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023

NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Guangzhou (GNC-038)

Not yet recruiting
  • NK/T Cell Lymphoma
  • +2 more
  • Guangzhou, Guangdong, China
  • +1 more
Jan 12, 2023

Peripheral T Cell Lymphoma Trial in Shandong, Shanghai, Sichuan (84-gene penal)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • 84-gene penal
  • Shandong, China
  • +2 more
Jul 6, 2023

T Lymphoblastic Leukemia/Lymphoma Trial in Shenzhen (CD7 CAR-T cells)

Recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • CD7 CAR-T cells
  • Shenzhen, Guangdong, China
    Li Yu
Nov 11, 2022

Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Tampa (Comprehensive Ablative Bridging Irradiation (CABI),

Recruiting
  • Large B-cell Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • Comprehensive Ablative Bridging Irradiation (CABI)
  • Chimeric Antigen Receptor T-Cell Therapy
  • Tampa, Florida
    Moffitt Cancer Center
Oct 26, 2023

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

Large B-cell Lymphoma Trial (Glofitamab, Polatuzumab vedotin, Obinutuzumab)

Not yet recruiting
  • Large B-cell Lymphoma
  • (no location specified)
Oct 3, 2023

Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • CAR-T Therapy
  • Hefei, Anhui, China
  • +7 more
Jul 31, 2023

Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell

Active, not recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 30, 2023